Search results
Added:
1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only…
View more
Pulmonary Embolism Management
Start date:
Oct 07, 2025
Broadcast
Start date:
Jul 02, 2025
.img-row:after {
content: "";
clear: both;
display: table;
}
.img-column {
float: left;
width: 50%;
padding: 5px;
}
@media screen and (max-width: 500px) {
.img-column {
width: 100%;
}
}
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)…
View more
Added:
1 year ago
Added:
4 months ago
Systematic Scoping on DOACS in NVAF Patients
Added:
6 months ago
Review Article
Added:
7 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more
Added:
3 weeks ago
Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss evolving strategies for stroke management following atrial fibrillation ablation, addressing the critical question of when anticoagulation can be safely discontinued after successful ablation.Interview Questions:There's been a lot of talk about optimal anticoagulation – what's the headline? In which…
View more
Added:
2 months ago
In this interview, Prof Michael Joner (German Heart Centre, Munich, DE) discusses the specific needs and treatment considerations when managing low and intermediate risk TAVI patients. He also highlights the increasing need to consider future interventions when selecting the index valve.Prof Joner details the Navitor TAVI system resheathable design with intra-annular function, large-cell frame…
View more
The Next Frontier in Amyloidosis Management
Video Series